Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Brzozow – page 2

41 clinical trials in Brzozow, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Brzozow at a glance
41
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

41 trials in Brzozow

Open in trial search

Chronic lymphocytic leukaemia+1

Recruiting

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not yet recruiting

Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Acute lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Study on Bendamustine, Rituximab, and Acalabrutinib for Patients with Untreated Mantle Cell Lymphoma

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Plasma cell myeloma refractory

Not recruiting

A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
  • Sponsor:Janssen Cilag International

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

B-cell lymphoma

Not recruiting

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Brzozow

What the registry says about research in the country

01 Hematologic Malignancies

Groundbreaking clinical trials focusing on multiple myeloma, leukemia, and lymphoma treatments. Studies evaluate novel combination therapies and targeted approaches for both newly diagnosed and relapsed/refractory patients.

  • Multiple Myeloma Treatment Innovations
  • Chronic Lymphocytic Leukemia Research
  • Mantle Cell Lymphoma Therapies

Research includes evaluation of monoclonal antibodies, targeted therapies, and immunotherapy combinations.

02 Gastrointestinal Oncology

Studies examining advanced treatments for gastric cancer and colorectal cancer, with particular focus on targeted therapies for specific genetic mutations and biomarker-driven approaches.

  • BRAF-Mutant Colorectal Cancer
  • Gastroesophageal Junction Cancer
  • Novel Combination Therapies

Trials incorporate innovative treatment combinations including immunotherapy and targeted agents.

03 Advanced Therapeutics

Cutting-edge research evaluating personalized treatment strategies across various cancer types, including studies of novel drug combinations and targeted approaches for rare conditions.

  • Myeloproliferative Disorders
  • Breast Cancer Innovations
  • Renal Cell Carcinoma Treatment

Focus on precision medicine approaches and biomarker-driven treatment selection.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.